ESG Intelligence – Pharmaceuticals – 1st December 2020 to 28th February 2021

The average ESG score (-20) for companies across the sector declines significantly in comparison to the previous three-month period. ‘Affordability & Pricing’ dominates discussion in late-January due to multiple price hikes across the sector, and again in mid-February as several companies refuse to sell therapies at the legally required 340B price; 12 firms score negatively on this issue. Biogen & Roche lawsuits contribute negatively to ‘Business Ethics’ with bribery and corruption claims against a number of firms prevalent in social media coverage. Praise for Covid vaccination research and collaborations notably drops off.

Download the full report here.